NAD + biosynthesis, aging, and disease
- PMID: 29744033
- PMCID: PMC5795269
- DOI: 10.12688/f1000research.12120.1
NAD + biosynthesis, aging, and disease
Abstract
Nicotinamide adenine dinucleotide (NAD +) biosynthesis and its regulation have recently been attracting markedly increasing interest. Aging is marked by a systemic decrease in NAD + across multiple tissues. The dysfunction of NAD + biosynthesis plays a critical role in the pathophysiologies of multiple diseases, including age-associated metabolic disorders, neurodegenerative diseases, and mental disorders. As downstream effectors, NAD +-dependent enzymes, such as sirtuins, are involved in the progression of such disorders. These recent studies implicate NAD + biosynthesis as a potential target for preventing and treating age-associated diseases. Indeed, new studies have demonstrated the therapeutic potential of supplementing NAD + intermediates, such as nicotinamide mononucleotide and nicotinamide riboside, providing a proof of concept for the development of an effective anti-aging intervention.
Keywords: Biosynthesis Aging; NAD+.
Conflict of interest statement
No competing interests were disclosed.No competing interests were disclosed.No competing interests were disclosed.
Figures
References
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
